Puma Biotech jumps after U.S. patent term extension for cancer drug

Puma Biotechnology

24/11/2021 16:00

** Shares of drugmaker  PBYI.O  rise 10.4% to $3.51 
    ** Late on Tuesday, Puma Biotechnology said it received a
patent term extension of five years for its breast cancer drug
Nerlynx  urn:newsml:reuters.com:*:nBw45PdK6a
    ** Says patent will now expire on Dec. 29, 2030
    ** Nerlynx is approved for use as an additional treatment
for adult patients with early stages of a type of breast cancer
and in combination with a chemotherapy for advanced breast
cancer
    ** Stock down 65.8% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))